FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer

Background: Resistance to endocrine treatments is a major clinical challenge in the management of estrogen receptor positive breast cancers. Although multiple mechanisms leading to endocrine resistance have been proposed, the poor outcome of this subgroup of patients demands additional studies. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellegrino, Michele, Rizza, Pietro, Donà, Ada, Nigro, Alessandra, Ricci, Elena, Fiorillo, Marco, Perrotta, Ida, Lanzino, Marilena, Giordano, Cinzia, Bonofiglio, Daniela, Bruno, Rosalinda, Sotgia, Federica, Lisanti, Michael P., Sisci, Diego, Morelli, Catia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966564/
https://www.ncbi.nlm.nih.gov/pubmed/31769419
http://dx.doi.org/10.3390/cancers11121858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966564/
https://www.ncbi.nlm.nih.gov/pubmed/31769419
http://dx.doi.org/10.3390/cancers11121858

Ejemplares similares